Fezakinumab

Fezakinumab

Monoclonal antibody
Type	Whole antibody
Target	IL-22
Clinical data
ATC code	none
Identifiers
CAS Number	1007106-86-6 N
ChemSpider	none
UNII	0S77U25XZ3 Y
Chemical and physical data
Formula	C6408H9873N1706O2016S44
Molar mass	143.87 kg/mol
NY (what is this?)  (verify)

Fezakinumab is a human monoclonal antibody against interleukin-22,^[1] designed for the treatment of psoriasis and rheumatoid arthritis.^[2]

Wyeth discovered and initially developed the drug, and clinical development continued after that company was acquired by Pfizer. Fezakinumab, in combination with methotrexate, completed a phase II trial in rheumatoid arthritis, ^[3] but data was not released. Development was discontinued in August 2011.

References

1. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Fezakinumab" (PDF). American Medical Association. 
2. ↑ page 6; http://www.pfizer.com/files/research/pipeline/2011_0228/pipeline_2011_0228.pdf
3. ↑ http://lmt.projectsinknowledge.com/Activity/index.cfm?showfile=b&jn=2016&sj=2016.05&sc=2016.05.4

javascript:void(0);